Role of Bone Morphogenetic Protein 2 Polymorphisms in Bone Mineral Density after the Start of Treatment with Atorvastatin

Basic Clin Pharmacol Toxicol. 2018 Dec;123(6):766-769. doi: 10.1111/bcpt.13086. Epub 2018 Aug 2.
No abstract available

MeSH terms

  • Absorptiometry, Photon
  • Atorvastatin / administration & dosage
  • Atorvastatin / pharmacology*
  • Bone Density / drug effects
  • Bone Density / genetics*
  • Bone Morphogenetic Protein 2 / genetics*
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Lipids / blood
  • Male
  • Middle Aged
  • Polymorphism, Genetic*

Substances

  • BMP2 protein, human
  • Bone Morphogenetic Protein 2
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipids
  • Atorvastatin